Endocrine Resistance: Emerging Mechanisms and Therapies in Metastatic ER+ Breast Cancer - Enduring
According to NCB there are more than 27,000 articles on the topic of breast cancer in the human species alone in the last 4 years. The number and breadth of the publications make it difficult for participating physicians to maintain current knowledge and competence in application of recent developments. This activity will bridge the gap of current practice to include recent developments in disease classification, molecular biology, diagnostic algorithms, testing modalities and therapeutic advances.
Practicing clinicians and advanced trainees with interest in breast cancer and other allied health care professionals interested in the treatment of patients with breast cancer.
- Describe recent developments in the diagnosis, classification, and molecular biology of breast cancer.
- Recognize the impact of new developments on targeted and personalized therapy.
- Implement current best practices for diagnosis, classification, and detection of prognostic and therapeutic markers.
This activity has been planned and implemented in strict compliance with the accreditation requirements, standards, and policies of the ACCME. City of Hope takes responsibility for the content, quality and scientific integrity of this CME activity.
As an accredited CME provider City of Hope requires everyone who is in a position to control the content of an educational activity to disclose all relevant financial relationships with any commercial interest. The ACCME defines "relevant financial relationships" as financial relationships in any amount, occurring within the past 24 months, including financial relationships of a spouse that could create a conflict of interest. Any potential conflicts relative to the previous disclosure have been resolved.
Presenter: Dr. Ingrid A. Mayer has indicated that she receives Grant/Research Support from AstraZeneca, Genentech, Immunomedics, Lilly, Pfizer & Puma; and is a Consultant for AbbVie, AstraZeneca, Blueprint Medicines, Cyclacel, Genentech, GlaxoSmithKlein, Immunomedics, Lilly, Macrogenics, Novartis, Pfizer, Puma & Seagen.
City of Hope further encourages faculty/ authors to identify investigational products or off-label uses of products regulated by the U.S. Food and Drug Administration, at first mention and where appropriate in the content.
This activity will include a discussion of the off-label or investigational use of selective Estrogen Receptor Degraders (SERDs), Neratinib, Erdafitinib, and Enobosarm.
The information and opinions presented in this activity do not constitute medical or legal advice. Health care providers must exercise their own professional judgment in their clinical practice, and when confronted with the issues discussed herein, should not substitute this curriculum for the advice of legal counsel or application of sound ethical principles.
Endocrine Resistance: Emerging Mechanisms and Therapies in Metastatic ER+ Breast Cancer - Enduring has received no commercial support.
ACCREDITATION STATEMENT: City of Hope is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
CREDIT DESIGNATION: City of Hope designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
The following credit type(s) are being offered for this course:
• AMA PRA Category 1 Credit™ 1.0
The following may apply AMA PRA Category 1 Credit™ for license renewal:
Registered Nurses: Nurses may report up to 1.0 credit hours toward the continuing education requirements for license renewal by their state Board of Registered Nurses (BRN). AMA PRA Category 1 Credit™ may be noted on the license renewal application in lieu of a BRN provider number.
Physician Assistants: The National Commission on Certification of Physicians Assistants states that AMA PRA Category 1 Credit™ accredited courses are acceptable for CME requirements for recertification.
- 1.00 AMA PRA Category 1 Credit™City of Hope is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
City of Hope designates this Endocrine Resistance: Emerging Mechanisms and Therapies in Metastatic ER+ Breast Cancer - Enduring for a maximum of 1.00 AMA PRA Category 1 Credit™ requirements. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
- 1.00 Attendance
You must be logged in to access this Enduring.
If you are a New User, please create an account first, by clicking on "Register".
Once Logged in:
Click on "Start Activity" to access the educational content for this Enduring activity.